Factor VII Deficiency

ABSTRACT

The complex formed between the procoagulant serine protease activated factor VII (FVII) and the membrane protein tissue factor, exposed on the vascular lumen upon injury, triggers the initiation of blood clotting. This review describes the clinical picture of FVII deficiency and provides information on diagnosis and management of the disease. FVII deficiency, the most common among the rare congenital coagulation disorders, is transmitted with autosomal recessive inheritance. Clinical phenotypes range from asymptomatic condition, even in homozygotes, to severe disease characterized by life-threatening and disabling symptoms (central nervous system and gastrointestinal bleeding and hemarthrosis), with early age of presentation and the need for prophylaxis. In females, menorrhagia is prevalent and affects two thirds of the patients of fertile age. Although FVII gene mutations are extremely heterogeneous, several recurrent mutations have been reported, a few of them relatively frequent. The study of genotype-phenotype relationships indicates that modifier (environmental and/or inherited) components modulate expressivity of FVII deficiency, as reflected by patients with identical FVII mutations and discordant clinical phenotypes. Several treatment options are available for FVII deficiency: the most effective are plasma-derived FVII concentrates and recombinant activated FVII (rFVIIa). Treatment-related side effects are rare.

KEYWORDS

FVII deficiency - F7 database - F7 genotypes - FVII bleeding phenotype - replacement therapy

REFERENCES

• 1 Morissey J H, Mutch N J. Tissue factor structure and function. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Thrombosis and Haemostasis. Basic Principles and Clinical Practice, 5th ed. p. 91
• 2 Butenas S, van't Veer C, Mann K G. “Normal” thrombin generation.  Blood. 1999;  94 2169-2178
• 3 Rapaport S I, Rao L V. The tissue factor pathway: how it has become a “prima ballerina”.  Thromb Haemost. 1995;  74 7-17
• 4 Triplett D A, Brandt J T, Batard M A, Dixon J L, Fair D S. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis.  Blood. 1985;  66 1284-1287
• 5 Roberts H R, Escobar M A. Less common congenital disorders of hemostasis. In: Kitchens CS, Alving BM, Kessler CM Consultative Hemostasis and Thrombosis. Philadelphia, PA; WB Saunders 2002: 57
• 6 Mariani G, Herrmann F H, Dolce A International Factor VII Deficiency Study Group et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency.  Thromb Haemost. 2005;  93 481-487
• 7 Rosen E D, Xu H, Liang Z, Martin J A, Suckow M, Castellino F J. Generation of genetically-altered mice producing very low levels of coagulation factorVII.  Thromb Haemost. 2005;  94 493-497
• 8 McVey J H, Boswell E, Mumford A D, Kemball-Cook G, Tuddenham E G. Factor VII deficiency and the FVII mutation database.  Hum Mutat. 2001;  17 3-17
• 9 Perry D J. Factor VII deficiency.  Br J Haematol. 2002;  118 689-700
• 10 Bernardi F, Castaman G, Pinotti M et al.. Mutation pattern in clinically asymptomatic coagulation factor VII deficiency.  Hum Mutat. 1996;  8 108-115
• 11 Millar D S, Kemball-Cook G, McVey J H et al.. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency.  Hum Genet. 2000;  107 327-342
• 12 Peyvandi F, Jenkins P V, Mannucci P M et al.. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency.  Thromb Haemost. 2000;  84 250-257
• 13 Herrmann F H, Wulff K, Auberger K et al.. Molecular biology and clinical manifestation of hereditary factor VII deficiency.  Semin Thromb Hemost. 2000;  26 393-400
• 14 Wulff K, Herrmann F H. Twenty two novel mutations of the factor VII gene in factor VII deficiency.  Hum Mutat. 2000;  15 489-496
• 15 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals.  Arterioscler Thromb. 1991;  11 540-546
• 16 Bernardi F, Marchetti G, Pinotti M et al.. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma.  Arterioscler Thromb Vasc Biol. 1996;  16 72-76
• 17 Giansily-Blaizot M, Verdier R, Biron-Adréani C Study group of FVII deficiency et al. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?.  Haematologica. 2004;  89 704-709
• 18 Lak M, Peyvandi F, Mannucci P M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.  Br J Haematol. 2000;  111 1236-1239
• 19 Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Frequency of inherited bleeding disorders in women with menorrhagia.  Lancet. 1998;  351 485-489
• 20 Mariani G, Herrmann F H, Schulman S International Factor VII Deficiency Study Group et al. Thrombosis in inherited factor VII deficiency.  J Thromb Haemost. 2003;  1 2153-2158
• 21 Marty S, Barro C, Chatelain B et al.. The paradoxical association between inherited factor VII deficiency and venous thrombosis.  Haemophilia. 2008;  14 564-570
• 22 Nicolaisen E M, Hansen L L, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use.  Thromb Haemost. 1996;  76 200-204
• 23 Nicolaisen E M. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.  Blood Coagul Fibrinolysis. 1998;  9(Suppl 1) S119-S123
• 24 Ingerslev J, Christiansen K, Sørensen B. International Registry on Factor VII Deficiency (IRF7) Steering Committee . Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response.  J Thromb Haemost. 2005;  3 799-800
• 25 Pruthi R K, Rodriguez V, Allen C, Slaby J A, Schmidt K A, Plumhoff E A. Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G).  Eur J Haematol. 2007;  79 354-359
• 26 Pinotti M, Etro D, Bindini D et al.. Residual factor VII activity and different hemorrhagic phenotypes in CRM(+) factor VII deficiencies (Gly331Ser and Gly283Ser).  Blood. 2002;  99 1495-1497
• 27 Mariani G, Hermans J, Orlando M et al.. Carrier detection in factor VII congenital deficiency.  Br J Haematol. 1985;  60 687-694
• 28 Mariani G, Liberti G, D'Angelo T, LoCoco L. Factor VII activity and antigen. In: Jespersen J, Bertina RM, Haverkate F Laboratory Techniques in Thrombosis. A Manual. Dordrecht, The Netherlands; Kluwer Academic Publishers 1999: 99-106
• 29 Castoldi E, Govers-Riemslag J W, Pinotti M et al.. Coinheritance of factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation.  Blood. 2003;  102 4014-4020
• 30 O'Hara P J, Grant F J, Haldeman B A et al.. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation.  Proc Natl Acad Sci U S A. 1987;  84 5158-5162
• 31 Hagen F S, Gray C L, O'Hara P et al.. Characterization of a cDNA coding for human factor VII.  Proc Natl Acad Sci U S A. 1986;  86 2412-2416
• 32 Pinotti M, Rizzotto L, Pinton P International Factor VII Deficiency Study Group et al. Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII.  J Thromb Haemost. 2006;  4 1308-1314
• 33 Bernardi F, Patracchini P, Gemmati D et al.. Molecular analysis of factor VII deficiency in Italy: a frequent mutation (FVII Lazio) in a repeated intronic region.  Hum Genet. 1993;  92 446-450
• 34 Kario K, Narita N, Matsuo T et al.. Genetic determinants of plasma factor VII activity in the Japanese.  Thromb Haemost. 1995;  73 617-622
• 35 Lippi G, Montagnana M, Salvagno G L, Poli G, Franchini M, Guidi G C. Influence of warfarin therapy on activated factor VII clotting activity.  Blood Coagul Fibrinolysis. 2006;  17 221-224
• 36 Giansily-Blaizot M, Thorel D, Khau Van Kien P et al.. Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency.  Br J Haematol. 2007;  138 359-365
• 37 Garagiola I, Palla R, Peyvandi F. Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency—misdiagnosis by direct sequence analysis using a PCR product.  Prenat Diagn. 2003;  23 731-734
• 38 Mariani G, Konkle B A, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII—a critical appraisal.  Haemophilia. 2006;  12 19-27
• 39 Hoffman M. Some things I thought I knew about tissue factor that turn out to be wrong.  Thromb Res. 2008;  122(Suppl 1) S73-S77
• 40 Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P et al.. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding.  Br J Haematol. 2002;  117 172-175
• 41 Mariani G, Mannucci P M, Mazzucconi M G, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate.  Thromb Haemost. 1978;  39 675-682
• 42 Berrettini M, Mariani G, Schiavoni M et al.. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.  Haematologica. 2001;  86 640-645
• 43 Kulkarni A A, Lee C A, Kadir R A. Pregnancy in women with congenital factor VII deficiency.  Haemophilia. 2006;  12 413-416